← Back to headlines
Coherus BioSciences, Halozyme Therapeutics Post Quarterly Results
Coherus BioSciences reported non-GAAP EPS of -$0.25, beating estimates, but missed revenue targets, while Halozyme Therapeutics exceeded expectations with non-GAAP EPS of $1.60 and revenue of $376.71 million.
11 May, 20:16 — 11 May, 20:16
Sources
Showing 1 of 1 sources
